Artivion (AORT) 10-Q 1 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 26, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Central Index Key	784,199
Entity Registrant Name	CRYOLIFE INC
Trading Symbol	cry
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		36,967,506

Consolidated Statements Of Oper

Consolidated Statements Of Operations And Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 64,598	$ 43,999	$ 195,042	$ 136,876
Cost of products and preservation services:
Total cost of products and preservation services	21,884	14,137	67,249	44,597
Gross margin	42,714	29,862	127,793	92,279
Operating expenses:
General, administrative, and marketing	32,871	24,756	104,946	71,016
Research and development	5,225	4,277	16,314	13,098
Total operating expenses	38,096	29,033	121,260	84,114
Operating income	4,618	829	6,533	8,165
Interest expense	4,104	851	11,863	2,486
Interest income	(52)	(64)	(141)	(159)
Other (income) expense, net	(1,542)	21	(257)	(70)
Income (loss) before income taxes	2,108	21	(4,932)	5,908
Income tax expense (benefit)	543	(1,304)	(2,868)	(803)
Net income (loss)	$ 1,565	$ 1,325	$ (2,064)	$ 6,711
Income (loss) per common share:
Basic	$ 0.04	$ 0.04	$ (0.06)	$ 0.20
Diluted	$ 0.04	$ 0.04	$ (0.06)	$ 0.19
Weighted-average common shares outstanding:
Basic	36,526	32,887	36,331	32,665
Diluted	37,610	34,057	36,331	33,851
Net income (loss)	$ 1,565	$ 1,325	$ (2,064)	$ 6,711
Other comprehensive income (loss):
Foreign currency translation adjustments	(514)	217	(5,140)	582
Comprehensive income (loss)	1,051	1,542	(7,204)	7,293
Products [Member]
Revenues:
Total revenues	45,152	27,029	138,063	84,519
Cost of products and preservation services:
Total cost of products and preservation services	12,459	6,220	40,166	21,196
Preservation Services [Member]
Revenues:
Total revenues	19,446	16,970	56,979	52,357
Cost of products and preservation services:
Total cost of products and preservation services	$ 9,425	$ 7,917	$ 27,083	$ 23,401

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 34,558	$ 39,977
Restricted securities	753	776
Receivables, net	48,882	47,525
Receivables:
Other receivables	3,974	3,916
Inventories	46,149	46,684
Deferred preservation costs	33,509	35,671
Prepaid expenses and other	6,127	4,731
Total current assets	173,952	179,280
Property and equipment, net	32,072	33,579
Goodwill	188,118	188,305
Net intangible assets	121,254	130,359
Other intangibles, net	42,184	49,071
Other	12,115	9,099
Total assets	569,695	589,693
Current liabilities:
Accounts payable	5,941	9,767
Accrued compensation	8,628	10,208
Current portion of long-term debt	1,266	718
Taxes payable	924	4,020
Accrued expenses and other	13,990	18,227
Total current liabilities	30,749	42,940
Long-term debt	216,579	218,236
Deferred income taxes	26,116	30,431
Other	19,444	21,028
Total liabilities	292,888	312,635
Commitments and contingencies
Shareholders' equity:
Preferred stock
Common stock (issued shares of 38,445 in 2018 and 37,618 in 2017)	384	376
Additional paid-in capital	258,555	249,935
Retained earnings	35,742	37,609
Accumulated other comprehensive (loss) income	(3,283)	1,857
Treasury stock at cost (shares of 1,484 in 2018 and 1,387 in 2017)	(14,591)	(12,719)
Total shareholders' equity	276,807	277,058
Total liabilities and shareholders' equity	$ 569,695	$ 589,693

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Sep. 30, 2018	Dec. 31, 2017
Shareholders' equity:
Common stock, shares issued	38,445	37,618
Treasury stock at cost, shares	1,484	1,387

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net cash flows from operating activities:
Net income (loss)	$ (2,064)	$ 6,711
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	13,636	6,683
Non-cash compensation	4,685	5,652
Other non-cash adjustments to (loss) income	(1,330)	879
Changes in operating assets and liabilities:
Receivables	(2,310)	(4,303)
Inventories and deferred preservation costs	1,697	(6,901)
Prepaid expenses and other assets	(2,481)	(3,040)
Accounts payable, accrued expenses, and other liabilities	(12,473)	(855)
Net cash flows (used in) provided by operating activities	(640)	4,826
Net cash flows from investing activities:
Proceeds from sale of business component		740
Capital expenditures	(4,275)	(5,384)
Other	(722)	(67)
Net cash flows used in investing activities	(4,997)	(4,711)
Net cash flows from financing activities:
Repayment of term loan	(2,098)	(3,916)
Proceeds from exercise of stock options and issuance of common stock	3,793	2,599
Redemption and repurchase of stock to cover tax withholdings	(2,085)	(1,600)
Other	(888)	(3)
Net cash flows used in financing activities	(1,278)	(2,920)
Effect of exchange rate changes on cash, cash equivalents, and restricted securities	1,473	477
Decrease in cash, cash equivalents, and restricted securities	(5,442)	(2,328)
Cash, cash equivalents, and restricted securities beginning of period	40,753	57,341
Cash, cash equivalents, and restricted securities end of period	$ 35,311	$ 55,013

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2018
Basis Of Presentation [Abstract]
Basis Of Presentation	1. Basis of Presentation  Overview  The accompanying summary consolidated financial statements include the accounts of CryoLife, Inc. and its subsidiaries (“CryoLife,” the “Company,” “we,” or “us”) . All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying Summary Consolidated Balance Sheet as of December 31, 2017 has been derived from audited financial statements. The accompanying unaudited summary consolidated financial statements as of, and for the three and nine months ended , September 30, 2018 and 2017 have been prepared in accordance with (i) accounting principles generally accepted in the U.S. for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete presentation of financial statements. In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 . These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in CryoLife’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 9, 2018.  New Accounting Standards  Recently Adopted  As of January 1, 2018 we adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers and the additional related ASUs (“ASC 606”). These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. ASC 606 provides that we recognize revenue to depict the transfer of control of promised goods or services to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We used the modified retrospective method applied to those contracts that were not substantially completed as of January 1, 2018 . As a result of the adoption, we recorded an immaterial adjustment to increase retained earnings to recognize the impact of contract assets under the new revenue recognition guidance. See Note 11 for further discussion of revenue recognition.  In August 2016 the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016 ‑18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016 ‑18”). ASU 2016-18 is intended to address diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows. The guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We adopted ASU 2016-18 as of January 1, 2018 and disclosure revisions have been made for the periods presented on the Summary Consolidated Statement of Cash Flows .  Not Yet Effective  In February 2016 the FASB amended its Accounting Standards Codification (“ASC”) and created a new Topic 842, Leases . The final guidance requires lessees to recognize a right-of-use asset and a lease liability for all leases (with the exception of short-term leases) at the commencement date and recognize expenses on their income statements similar to the current Topic 840, Leases . It is effective for fiscal years and interim periods beginning after December 15, 2018, and early adoption is permitted. We have identified contracts with potential leasing arrangements, entered leases into a tracking software, and are currently evaluating the impact the adoption of this standard will have on our financial position, results of operations, and cash flows.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2018
Financial Instruments [Abstract]
Financial Instruments	2. Financial Instruments The following is a summary of our financial instruments measured at fair value (in thousands):     September 30, 2018 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 1,237 $ -- $ -- $ 1,237  Restricted securities:  Money market funds 753 -- -- 753  Total assets $ 1,990 $ -- $ -- $ 1,990     December 31, 2017 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 372 $ -- $ -- $ 372  Restricted securities:  Money market funds 776 -- -- 776  Total assets $ 1,148 $ -- $ -- $ 1,148  We used prices quoted from our investment advisors to determine the Level 1 valuation of our investments in money market funds.

Cash Equivalents And Restricted

Cash Equivalents And Restricted Securities	9 Months Ended
	Sep. 30, 2018
Cash Equivalents And Restricted Securities [Abstract]
Cash Equivalents And Restricted Securities	3. Cash Equivalents and Restricted Securities  The following is a summary of cash equivalents and restricted securities (in thousands):    Unrealized Estimated  Holding Market  September 30, 2018 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 1,237 $ -- $ 1,237  Restricted securities:  Money market funds 753 -- 753   Unrealized Estimated  Holding Market  December 31, 2017 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 372 $ -- $ 372  Restricted securities:  Money market funds 776 -- 776 As of September 30, 2018 and December 31, 2017 $753,000 and $776,000 , respectively, of our money market funds were designated as short-term restricted securities due to a contractual commitment to hold the securities as pledged collateral relating primarily to international tax obligations.  There were no gross realized gains or losses on cash equivalents in the three and nine months ended September 30, 2018 and 2017 . As of September 30, 2018 $231,000 of our restricted securities had a maturity date within three months and $ 522,000 of our restricted securities had a maturity date between three months and one year. As of December 31, 2017 $537,000 of our restricted securities had a maturity date within three months and $239,000 had a maturity date between three months and one year.

Acquisition Of JOTEC

Acquisition Of JOTEC	9 Months Ended
	Sep. 30, 2018
Acquisition Of JOTEC [Abstract]
Acquisition of JOTEC	4. Acquisition of JOTEC  Overview  On December 1, 2017 we acquired JOTEC AG, a Swiss entity that we converted to JOTEC GmbH and subsequently merged with our Swiss acquisition entity, Jolly Buyer Acquisition GmbH (“JOTEC”), and its subsidiaries (the “JOTEC Acquisition”) for a contract value of approximately $225.0 million, subject to certain adjustments. JOTEC is being operated as a wholly-owned subsidiary of CryoLife. In connection with the closing of the JOTEC Acquisition, CryoLife entered into a senior secured credit facility in an aggregate principal amount of $255.0 million, which includes a $225.0 million term loan and a $30.0 million revolving credit facility. See Note 8 for further discussion of the senior secured credit facility.  Accounting for the Transaction  We have updated our preliminary analysis of the purchase price of the JOTEC Acquisition to $222.2 million, including debt and cash acquired as determined on the date of closing, consisting of $169.1 million in cash and 2,682,754 shares of CryoLife common stock, with a value of $53.1 million on the date of the closing. This purchase price reflects an additional payment related to a working capital true-up calculated and paid to the sellers as defined in the purchase agreement. Upon closing of the JOTEC Acquisition, $22.5 million was paid into an escrow account for any amounts payable for indemnification claims or other payment obligations. Our preliminary allocation of the $222.2 million purchase consideration was allocated to JOTEC’ s tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated fair values as of December 1, 2017. Goodwill was preliminarily recorded based on the amount by which the purchase price exceeded the fair value of the net assets acquired and is not deductible for tax purposes. Goodwill from this transaction has been allocated to our Medical Devices segment. The estimated allocation of assets acquired and liabilities assumed is based on the information available to us. As we complete our valuation procedures , if new information regarding these values is received that would result in a material adjustment to the values recorded, we will recognize the adjustment, which may include the recognition of additional expenses, impairments, or other allocation adjustments, in the period this determination is made. As of September 30, 2018 goodwill increased by $ 3.2 million resulting from adjustments made during the measurement period, prima rily related to certain intangible assets.  The preliminary purchase price allocation as of December 1, 2017, reflecting the measurement period adjustments is as follows (in thousands):     Opening  Balance Sheet  Cash and cash equivalents $ 4,130  Receivables 13,392  Inventories 17,393  Intangible assets 111,711  Property and equipment, net 13,051  Goodwill 112,431  Other assets 4,281  Debt acquired (3,808)  Liabilities assumed (50,424)  Total purchase price $ 222,157  We incurred transaction and integration costs of $1.8 million and $6.1 million for the three and nine months ended September 30, 2018 related to the JOTEC Acquisition, which included, among other costs, expenses related to the termination of international distribution agreements, severance costs, and legal, other professional, and consulting costs. These costs were expensed as incurred and were primarily recorded as general, administrative, and marketing expenses on our Summary Consolidated Statements of Operations and Comprehensive Income (Loss).  Pro Forma Results - Unaudited  JOTEC revenues were $4.1 million and the net loss was $1.5 million from the date of the JOTEC Acquisition through December 31, 2017. Our unaudited pro forma results of operations for the years ended December 31, 2017 and 2016, assuming the JOTEC Acquisition had occurred as of January 1, 2016, are presented for comparative purposes below. These amounts are based on available information from the results of operations of JOTEC prior to the acquisition date and are not necessarily indicative of what the results of operations would have been had the JOTEC Acquisition been completed on January 1, 2016. Differences between the preliminary and final purchase price allocation could have an impact on the pro forma financial information presented below and that impact could be material. This unaudited pro forma information does not project operating results post JOTEC Acquisition.  A summary of this unaudited pro forma information is as follows (in thousands, except per share amounts):     Twelve Months Ended  December 31,  2017 2016  Total revenues $ 236,209 $ 224,896  Net loss (736) (1,966)   Pro forma loss per common share - basic $ (0.02) $ (0.06)  Pro forma loss per common share - diluted $ (0.02) $ (0.06) Pro forma net loss was calculated using a normalized tax rate of approximately 38% .

Inventories And Deferred Preser

Inventories And Deferred Preservation Costs	9 Months Ended
	Sep. 30, 2018
Inventories And Deferred Preservation Costs [Abstract]
Inventories And Deferred Preservation Costs	5. Inventories and Deferred Preservation Costs Inventories at September 30, 2018 and December 31, 2017 were comprised of the following (in thousands):    September 30, December 31,  2018 2017  Raw materials and supplies $ 16,858 $ 16,328  Work-in-process 4,093 5,504  Finished goods 25,198 24,852  Total inventories $ 46,149 $ 46,684  Deferred preservation costs at September 30, 2018 and December 31, 2017 were comprised of the following (in thousands):    September 30, December 31,  2018 2017  Cardiac tissues $ 16,077 $ 16,988  Vascular tissues 17,432 18,683  Total deferred preservation costs $ 33,509 $ 35,671  To facilitate patient support and access, we maintain consignment inventory of our On-X Life Technologies Holdings, Inc. (“On-X”) heart valves at domestic and international hospital locations and JOTEC products at international hospital locations. We retain title to this consignment inventory and it is included in finished goods inventory until the device is implanted, at which time we invoice the hospital. As of September 30, 2018 we had $10.6 million in consignment inventory, with approximately 58% in domestic locations and 42% in foreign locations. As of December 31, 2017 we had $9.3 million in consignment inventory with approximately 58% in domestic locations and 42% in foreign locations.

Goodwill And Other Intangible A

Goodwill And Other Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill And Other Intangible Assets [Abstract]
Goodwill And Other Intangible Assets	6. Goodwill and Other Intangible Assets Indefinite Lived Intangible Assets As of September 30, 2018 and December 31, 2017 the carrying values of our indefinite lived intangible assets were as follows (in thousands):     September 30, December 31,  2018 2017  Goodwill $ 188,118 $ 188,305  In-process R&D 9,485 13,954  Procurement contracts and agreements 2,013 2,013  Trademarks 841 841  Based on our experience with similar agreements, we believe that our acquired procurement contracts and agreements have indefinite useful lives, as we expect to continue to renew these contracts for the foreseeable future. We believe that our trademarks have indefinite useful lives as we currently anticipate that our trademarks will contribute to our cash flows indefinitely.  We monitor the phases of development of all in-process R&D projects, including the risks associated with further development and the amount and timing of benefits expected to be derived from the completed projects. Incremental costs associated with development are charged to expense as incurred. Capitalized costs are amortized over the estimated useful life of the developed asset once completed. All in-process R&D projects are reviewed for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired.  As of September 30, 2018 and December 31, 2017 our entire goodwill balance was related to our Medical Devices segment.     Medical Devices Segment  Balance as of December 31, 2017 $ 188,305  JOTEC Acquisition measurement period adjustments 3,177  Revaluation of goodwill denominated in foreign currency (3,364)  Balance as of September 30, 2018 $ 188,118  Definite Lived Intangible Assets As of September 30, 2018 and December 31, 2017 the gross carrying values, accumulated amortization, and approximate amortization period of our definite lived intangible assets were as follows (in thousands):     Gross Carrying Accumulated Amortization  September 30, 2018 Value Amortization Period  Acquired technology $ 136,061 $ 14,807 11 – 22 Years  Customer lists and relationships 31,191 4,702 13 – 22 Years  Distribution and manufacturing rights and know-how 4,059 2,035 11 – 15 Years  Patents 3,621 2,918 17 Years  Other 2,096 1,467 3 – 5 Years   Gross Carrying Accumulated Amortization  December 31, 2017 Value Amortization Period  Acquired technology $ 139,045 $ 8,686 11 – 22 Years  Customer lists and relationships 32,419 3,552 13 – 23 Years  Distribution and manufacturing rights and know-how 4,059 1,820 11 – 15 Years  Patents 3,612 2,819 17 Years  Other 1,439 1,075 3 Years  Amortization Expense  The following is a summary of amortization expense as recorded in general, administrative, and marketing expenses on our Summary Consolidated Statement of Operations and Comprehensive Income (Loss) (in thousands):    Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Amortization expense $ 2,707 $ 1,140 $ 8,195 $ 3,423   As of September 30, 2018 scheduled amortization of intangible assets for the next five years is as follows (in thousands):    Remainder  of 2018 2019 2020 2021 2022 2023 Total  Amortization expense $ 2,597 $ 10,386 $ 10,222 $ 10,202 $ 9,673 $ 9,287 $ 52,367

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Taxes [Abstract]
Income Taxes	7. Income Taxes Income Tax Expense  Our effective income tax rate was an expense of 26% and a benefit of 58% for the three and nine months ended September 30, 2018 , respectively. Our effective income tax rate for the three months ended September 30, 2017 was not meaningful due to the impact of the value of tax adjustments as compared to the low amount of income before taxes. Our effective income tax rate was a benefit of 14% for the nine months ended September 30, 2017 due to the impact of the value of tax adjustments. Our income tax rate for the three and nine months ended September 30, 2018 was affected by excess tax benefit deductions related to stock compensation, which increased the year-to-date income tax benefits by approximately $1.4 million, and losses in high rate jurisdictions. These factors were partially offset by the effects of non-deductible operating expenses and executive compensation expenses .  Our income tax rate for the three and nine months ended September 30, 2017 was favorably affected by excess tax benefits, primarily related to the exercise of non-qualified stock options and the vesting of stock awards, which decreased income tax expense by approximately $1.1 million and $2.7 million, respectively.  On December 22, 2017 the U.S. enacted tax reform legislation known as the H.R. 1, commonly referred to as the “Tax Cuts and Jobs Act” (the “Tax Act”), resulting in significant modifications to existing law. We have elected to follow the guidance in SEC Staff Accounting Bulletin 118 (“SAB 118”), which provides additional clarification regarding the application of ASC Topic 740 , Income Taxes (“ASC 740”) in situations where we do not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Tax Act for the reporting period in which the Tax Act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the Tax Act’s enactment date and ending when we have obtained, prepared, and analyzed the information needed in order to complete the accounting requirements , but the measurement period cannot extend beyond one year from the enactment date.  As of September 30, 2018 we have not fully completed our accounting for the income tax effects of all elements of the Tax Act, but we have completed our analysis of the 2017 repatriation transition tax. Our final transition tax calculation was not materially different from the provisional nominal tax benefit recorded at December 31, 2017. For elements of the Tax Act for which our analysis is not yet complete, we made reasonable estimates of the effects and recorded provisional adjustments. If we were not yet able to make reasonable estimates of the impact of certain elements, we have not recorded any adjustments related to those elements and have continued accounting for them in accordance with ASC 740 based on the tax laws in effect before the Tax Act.  For our calendar year beginning in 2018, we are subject to several provisions of the Tax Act including computations under Global Intangible Low Taxed Income (“GILTI”), Foreign Derived Intangible Income (“FDII”), Base Erosion and Anti-Abuse Tax (“BEAT”), and Internal Revenue Code Section 163(j) interest limitation (“Interest Limitation”) rules. Based on preliminary information and analysis, we have recorded a provisional estimate for a FDII deduction of $565,000 in our effective tax rate for the nine months ended September 30, 2018 . We estimate the Interest Limitation will apply, but not affect our 2018 tax rate. We are not subject to BEAT at this time based on revenue trends. We will continue to refine our provisional estimates for our computations of the GILTI, FDII, and Interest Limitation rules as we gather additional information.  We currently estimate that other provisions of the Tax Act generally will not materially impact our 2018 effective rate, other than the potential impact of changes to the deductibility of meals and entertainment and executive compensation. We continue to gather new information on the interpretation of these new law changes and refine our provisional estimates.  As we complete our analysis of the Tax Act, further collect and analyze data, interpret any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service, and other standard-setting bodies, we may adjust our provisional amounts. Those adjustments may materially impact our provision for income taxes.  Deferred Income Taxes  We generate deferred tax assets primarily as a result of write-downs of inventory and deferred preservation costs , accruals for product and tissue processing liability claims , investment and asset impairments , and due to operating losses. We acquired significant deferred tax assets, primarily net operating loss carryforwards, from our acquisitions of JOTEC in 2017, On-X in 2016, Hemosphere, Inc. in 2012, and Cardiogenesis Corporation in 2011. We believe utilization of these net operating losses will not have a material impact on income taxes for the 2018 tax year. We recorded significant deferred tax liabilities in 2017 related to the intangible assets acquired in the JOTEC Acquisition.  As of September 30, 2018 we maintained a total of $2.5 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and had a net deferred tax liability of $22.7 million. As of December 31, 2017 we had a total of $ 2.5 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and a net deferred tax liability of $ 28.8 million.

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt [Abstract]
Debt	8. Debt Credit Agreement  On December 1, 2017 we entered into a credit and guaranty agreement for a new $255.0 million senior secured credit facility, consisting of a $225.0 million secured term loan facility (the “Term Loan Facility”) and a $30.0 million secured revolving credit facility (“the Revolving Credit Facility” a nd, together with the Term Loan Facility, the “Credit Agreement”). We and each of our existing domestic subsidiaries (subject to certain exceptions and exclusions) guarantee the obligations under the Credit Agreement (the “Guarantors”). The Credit Agreement is secured by a security interest in substantially all existing and after-acquired real and personal property (subject to certain exceptions and exclusions) of us and the Guarantors.  On December 1, 2017 we borrowed the entire $225.0 million Term Loan Facility . The proceeds of the Term Loan Facility were used along with cash on hand and shares of CryoLife common stock to (i) fund the JOTEC Acquisition, (ii) pay certain fees and expenses related to the JOTEC Acquisition and the Credit Agreement, and (iii) pay the outstanding balance of our prior credit facility. The Revolving Credit Facility is undrawn following the JOTEC Acquisition and may be used for working capital, capital expenditures, acquisitions permitted under the Credit Agreement, and other general corporate purposes pursuant to the terms of the Credit Agreement.  The loan under the Term Loan Facility is repayable on a quarterly basis according to the amortization provisions set forth in the Credit Agreement. We have the right to repay the loan under the Credit Agreement in whole or in part at any time. Amounts repaid in respect of the loan under the Term Loan Facility may not be reborrowed. Amounts repaid in respect of the loan under the Revolving Credit Facility may be reborrowed. All outstanding principal and interest in respect of (i) the Term Loan Facility must be repaid on or before December 1, 2024 and (ii) the Revolving Credit Facility must be repaid on or before December 1, 2022 . The loan under the Term Loan Facility bears interest, at our option, at a floating annual rate equal to either the base rate, plus a margin of 3.00% , or LIBOR, plus a margin of 4.00% . The loan under the Revolving Credit Facility bears interest, at our option, at a floating annual rate equal to either the base rate plus a margin of between 3.00% and 3.25% , depending on our consolidated leverage ratio, or LIBOR plus a margin of between 4.00% and 4.25% , depending on our consolidated leverage ratio. While a payment or bankruptcy event of default exists, we are obligated to pay a per annum default rate of interest of 2.00% in excess of the interest rate otherwise payable with respect to the overdue principal amount of any loans outstanding and overdue interest payments and other overdue fees and amounts. As of September 30, 2018 the aggregate interest rate was 6.39% per annum. We are obligated to pay an unused commitment fee equal to 0.50% of the un-utilized portion of the Revolving Credit Facility and are obligated to pay other customary fees for a credit facility of this size and type.  In October 2018 we finalized an amendment to the Credit Agreement to reprice, resulting in a reduction in the interest rate margin over LIBOR on the Term Loan Facility. Under the amendment to the Credit Agreement, the interest rates will be revised to a floating annual rate equal to either base rate, plus a margin of 2.25% , or LIBOR, plus a margin of 3.25%.  The Credit Agreement contains certain customary affirmative and negative covenants, including covenants that limit our ability, and the ability of our subsidiaries to, among other things, grant liens, incur debt, dispose of assets, make loans and investments, make acquisitions, make certain restricted payments, merge or consolidate, change their business or accounting or reporting practices, in each case subject to customary exceptions for a credit facility of this size and type. In addition, with respect to the Revolving Credit Facility, when the principal amount of loans outstanding thereunder is in excess of 25% of the Revolving Credit Facility, the Credit Agreement requires us to comply with a specified maximum first lien net leverage ratio. The Credit Agreement prohibits the payment of certain restricted payments, including cash dividends.  The Credit Agreement includes certain customary events of default that include, among other things, non-payment of principal, interest, or fees; inaccuracy of representations and warranties; breach of covenants; cross-default to certain material indebtedness; bankruptcy and insolvency; and change of control. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued but unpaid interest under the Credit Agreement immediately due and payable and may exercise the other rights and remedies provided under the Credit Agreement and related loan documents. As of September 30, 2018 and December 31, 2017 there were no outstanding balances on our Revolving Credit Facility and the remaining availability was $30.0 million.  Government Supported Bank Debt  In June 2015 JOTEC GmbH obtained two loans from Sparkasse Zollernalb, which we assumed in the acquisition, and are government sponsored by the Kreditanstalt für Wiederaufbau Bank (“KFW”). Both KFW loans have a term of 9 years and one loan bears an interest rate of 2.45% and the second loan bears an interest rate of 1.4 0 % .  Loan Balances  The short-term and long-term balances of our term loan and other borrowings were as follows (in thousands):    September 30, December 31,  2018 2017  Term loan balance $ 223,313 $ 225,000  2.45% Sparkasse Zollernalb (KFW Loan 1) 1,401 1,657  1.40% Sparkasse Zollernalb (KFW Loan 2) 1,989 2,312  Total loan balance 226,703 228,969  Less unamortized loan origination costs (8,858) (10,015)  Net borrowings 217,845 218,954  Less short-term loan balance (1,266) (718)  Long-term loan balance $ 216,579 $ 218,236  Interest Expense  Interest expense was $ 4.1 million and $11.9 million for the three and nine months ended September 30, 2018 , respectively, as compared to $851,000 and $2.5 million for the three and nine months ended September 30, 2017 , respectively. Interest expense for the three and nine months ended September 30, 2018 and 2017 included interest on debt and uncertain tax positions. The increase in interest expense in 2018 was due to the interest on borrowings under the $225.0 million secured term loan facility that we entered into in December 2017 to finance, in part, the JOTEC Acquisition.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies [Abstract]
Commitments And Contingencies	9. Commitments and Contingencies Liability Claims Our estimated unreported loss liability was $1.9 million and $1.8 million as of September 30, 2018 and December 31, 2017 , respectively. As of September 30, 2018 and December 31, 2017 , the related recoverable insurance amounts were $773,000 and $692,000 , respectively. We accrue our estimate of unreported product and tissue processing liability claims as a component of other long ‑term liabilities and record the related recoverable insurance amount as a component of other long ‑term assets, as appropriate. Further analysis indicated that the estimated liability as of September 30, 2018 could have been as high as $3.1 million, after including a reasonable margin for statistical fluctuations calculated based on actuarial simulation techniques.  Employment Agreements  The employment agreement of our Chairman, President, and Chief Executive Officer (“CEO”), Mr. J. Patrick Mackin, provides for a severance payment, which would become payable upon the occurrence of certain employment termination events, including termination by us without cause.  PerClot Technology  On September 28, 2010 we entered into a worldwide distribution agreement (the “Distribution Agreement”) and a license and manufacturing agreement (the “License Agreement”) with Starch Medical, Inc. (“ SMI”), for PerClot ® , a polysaccharide hemostatic agent used in surgery. The Distribution Agreement has a term of 15 years but can be terminated for any reason before the expiration date by us by providing 180 days’ notice. The Distribution Agreement also contains minimum purchase requirements that expire upon the termination of the Distribution Agreement or following U.S. regulatory approval for PerClot. Separate and apart from the terms of the Distribution Agreement, pursuant to the License Agreement, as amended by a September 2, 2011 technology transfer agreement, we can manufacture and sell PerClot, assuming appropriate regulatory approvals, in the U.S. and certain other jurisdictions and may be required to pay royalties to SMI at certain rates on net revenues of products.  We may make contingent payments to SMI of up to $1.0 million if certain U.S. regulatory and certain commercial milestones are achieved.  We are conducting our pivotal clinical trial to gain approval to commercialize PerClot for surgical indications in the U.S. Assuming enrollment proceeds as anticipated, we could receive Premarket Approval (“PMA”) from the U.S. Food and Drug Administration (“FDA”) in mid-year of 2020.  As of September 30, 2018 we had $ 1.5 million in prepaid royalties, $2.4 million in intangible assets, net , and $1.4 million in property and equipment, net on our Summary Consolidated Balance Sheets related to the PerClot product line. If we do not ultimately pursue or receive FDA approval to commercialize PerClot in the U.S., these assets could be materially impaired in future periods.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2018
Shareholders' Equity [Abstract]
Shareholders' Equity	10. Shareholders’ Equity Common Shares Issued  In December 2017 we issued 2,682,754 shares of CryoLife common stock, as part of the consideration for the acquisition of JOTEC. The stock had a value of $53.1 million as determined on the date of the closing. See Note 4 for further discussion of the JOTEC Acquisition. 

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Revenue Recognition	11. Revenue Recognition  Contracts with Customers  We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018 . These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition .  We routinely enter into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. These agreements, however, do not obligate us to provide goods or services to the customer , and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established by geography and by currency for all products and services , and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity.  Revenues for products, including: BioGlue ® Surgical Adhesive, On-X products, JOTEC products, PerClot, PhotoFix TM and other medical devices, are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is implanted. We recognize revenues for preservation services when services are completed and tissue is shipped to the customer.  Our E-xtra DESIGN ENGINEERING products are specifically designed to meet specifications of a particular patient, and therefore, do not create an asset with an alternative use. We evaluate open orders for these products each reporting period, and when material we recognize the revenue and related contract asset based on the amount of payment we believe we are entitled to at that time.  In certain limited circumstances, CardioGenesis cardiac laser consoles are provided to a customer for their use without transfer of title for evaluation purposes. We have determined that a portion of the revenue for the handpieces purchased during these evaluations constitutes revenue associated with the use of the laser console, but these are immaterial to reported revenues. Sources of Revenue  We have identified the following revenues disaggregated by revenue source:  1. Domestic Hospitals – direct sales of products and preservation services. 2. International Hospitals – direct sales of products and preservation services. 3. International Distributors – generally these contracts specify a geographic area that the distributor will service, terms and conditions of the relationship, and purchase targets for the next calendar year. 4. CardioGenesis Cardiac Laser Console Trials and Sales – CardioGenesis cardiac trialed laser consoles are delivered under separate agreements.  For the three and nine months ended September 30, 2018 and 2017 the sources of revenue were as follows (in thousands):     Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  (Unaudited) (Unaudited)  Domestic hospitals $ 34,924 $ 30,720 $ 103,606 $ 95,327  International hospitals 19,001 5,158 56,440 12,291  International distributors 9,083 6,632 30,482 24,128  CardioGenesis cardiac laser therapy 1,590 1,489 4,514 5,130  Total sources of revenue $ 64,598 $ 43,999 $ 195,042 $ 136,876  Also see segment and geographic disaggregation information in Note 14 below.  Contract Balances  We may generate contract assets during the pre-delivery design and manufacturing stage of E-xtra DESIGN ENGINEERING product order fulfillment. We assess the balance related to any arrangements in process and determine if the enforceable right to payment creates a material contract asset requiring disclosure.  We also incur contract obligations on general customer purchase orders that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product or service, we have determined that the balance related to these contract obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. The value of orders accepted but unfulfilled as of September 30, 2018 are not material.  Warranty  Our general product warranties do not extend beyond an assurance that the product or services delivered will be consistent with stated specifications and do not include separate performance obligations. Warranties included with our CardioGenesis cardiac laser products provide for annual maintenance services, which are priced separately and are recognized as revenues at the stand-alone price over the service period, whether invoiced separately or recognized based on our allocation of the transaction price.  Significant Judgments in the Application of the Guidance in ASC 606  There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product or service to the customer. This is consistent with the time in which the customer obtains control of the products or service. Performance obligations are also generally settled quickly after the purchase order acceptance, other than as identified for the E-xtra DESIGN ENGINEERING product, therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.  For performance obligations provided through our E-xtra DESIGN ENGINEERING product line, we determine the value of our enforceable right to payment based on the timing required and costs incurred for design services and manufacture of the in-process device in relation to the total inputs required to complete the device.  We consider variable consideration in establishing the transaction price. Forms of variable consideration potentially applicable to our arrangements include sales returns, rebates, volume- based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products and services in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Commissions and Contract Costs  Sales commissions are earned upon completion of each performance obligation, and therefore , are expensed when incurred. These costs are included in general, administrative, and marketing expenses in the Summary Consolidated Statements of Operations and Comprehensive Income (Loss). We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.  Practical Expedients  Our payment terms for sales direct to customers are substantially less than the one- year collection period that falls within the practical expedient in the determination of whether a significant financing component exists.  Shipping and Handling Charges  Fees charged to customers for shipping and handling of products and tissues are included in product revenues and preservation services revenues. The costs for shipping and handling of products and tissues are included as a component of cost of products and cost of preservation services.  Taxes Collected from Customers  Taxes collected on the value of transaction revenue are excluded from product and services revenues and cost of sales and are accrued in current liabilities until remitted to governmental authorities .  Effective Date and Transition Disclosures  Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements and is not expected to have a material impact in future periods. During our evaluation of the impact of adopting the new revenue standard, which included a detailed review of performance obligations for all material revenue streams, we identified two noteworthy items:  · Certain distributor agreements have historically included inventory buyback provisions under defined change of business conditions. Transactions under these terms would not qualify as a completed revenue transaction until sale through to the end customer, resulting in a revenue deferral until the proper criteria were satisfied. These agreements were modified or replaced to remove the buyback provisions effective on or before January 1, 2018 which eliminated any retrospective adjustment requirements. · Certain JOTEC products discussed above are manufactured to order, have no alternative use, and contain an enforceable right to receive payment for the performance completed. These factors qualify the transactions for revenue recognition over time. Upon adoption of the new standard, we evaluated all appropriate contracts in progress to determine the value of unbilled revenues representing outstanding contract assets. We recorded an immaterial cumulative effect adjustment to recognize the impact of contract assets.

Stock Compensation

Stock Compensation	9 Months Ended
	Sep. 30, 2018
Stock Compensation [Abstract]
Stock Compensation	12. Stock Compensation Overview  We have stock option and stock incentive plans for employees and non-employee Directors that provide for grants of restricted stock awards (“RSAs”), performance stock awards (“PSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of our common stock at exercise prices generally equal to the fair value of such stock at the dates of grant. We also maintain a shareholder-approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of our employees. The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85% of the market price at the beginning or end of each offering period.  Equity Grants During the nine months ended September 30, 2018 the Compensation Committee of our Board of Directors (the “Committee”) authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 317,000 shares and had an aggregate grant date market value of $7.1 million. The PSUs granted in 2018 represent the right to receive from 60% to 150% of the target number of shares of common stock. The performance component of PSU awards granted in 2018 is based on attaining specified levels of adjusted earnings before interest, taxes, depreciation, and amortization, (“ EBITDA ”) , as defined in the PSU grant documents, for the 2018 calendar year. We currently believe that achievement of the performance component is probable, and we reevaluate this likelihood on a quarterly basis.  During the nine months ended September 30, 2017 the Committee authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, including PSUs at target levels, together totaled 384,000 shares of common stock and had an aggregate grant date market value of $6.3 million . The PSUs granted in 2017 represented the right to receive from 60% to 150% of the target number of shares of common stock. The performance component of PSU awards granted in 2017 was based on attaining specified levels of adjusted EBITDA, adjusted inventory levels, and trade accounts receivable days’ sales outstanding, each as defined in the PSU grant documents, for the 2017 calendar year. The PSUs granted in 2017 earned 100% of the target number of shares.  The Committee authorized, from approved stock incentive plans, grants of stock options to purchase a total of 219,000 and 260,000 shares to certain Company officers during the nine months ended September 30, 2018 and 2017 , respectively. The exercise prices of the options were equal to the closing stock prices on their respective grant dates.  Employees purchased common stock totaling 46,000 and 82,000 shares in the three and nine months ended September 30, 2018 , respectively, and 47,000 and 93,000 shares in the three and nine months ended September 30, 2017 , respectively, through the ESPP.  Stock Compensation Expense The following weighted ‑average assumptions were used to determine the fair value of options:    Three Months Ended Nine Months Ended  September 30, 2018 September 30, 2018  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options N/A 0.5 Years 5.0 Years 0.5 Years  Expected stock price volatility N/A 0.32 0.40 0.35  Risk-free interest rate N/A 2.11% 2.64% 1.53%     Three Months Ended Nine Months Ended  September 30, 2017 September 30, 2017  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options N/A 0.5 Years 4.8 Years 0.5 Years  Expected stock price volatility N/A 0.43 0.40 0.35  Risk-free interest rate N/A 1.14% 1.87% 0.62%    The following table summarizes total stock compensation expenses prior to the capitalization of amounts into deferred preservation and inventory costs (in thousands):    Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  RSA, PSA, RSU, and PSU expense $ 1,281 $ 1,448 $ 3,750 $ 4,326  Stock option and ESPP option expense 412 519 1,301 1,614  Total stock compensation expense $ 1,693 $ 1,967 $ 5,051 $ 5,940   Included in the total stock compensation expense, as applicable in each period, were expenses related to RSAs, RSUs, PSUs, and stock options issued in each respective year, as well as those issued in prior periods that continue to vest during the period, and compensation related to the ESPP. The total stock compensation expense also included expenses related to PSAs during the three and nine months ended September 30, 2017 . We have not granted any other PSAs and there is no unrecognized compensation expense for PSAs. These amounts were recorded as stock compensation expense and were subject to our normal allocation of expenses to inventory costs and deferred preservation costs. We capitalized $125,000 and $363,000 in the three and nine months ended September 30, 2018 , respectively, and $111,000 and $288,000 in the three and nine months ended September 30, 2017 , respectively, of the stock compensation expense into our inventory costs and deferred preservation costs.  As of September 30, 2018 we had total unrecognized compensation costs of $7.9 million related to RSUs, RSAs, and PSUs and $2.2 million related to unvested stock options. As of September 30, 2018 this expense is expected to be recognized over a weighted-average period of 1.9 years for RSUs, 1.7 years for stock options, 1.2 years for RSAs, and 1.0 years for PSUs.

Income (Loss) Per Common Share

Income (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2018
Income (Loss) Per Common Share [Abstract]
Income (Loss) Per Common Share	13. Income (Loss) Per Common Share The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except per share data):     Three Months Ended Nine Months Ended  September 30, September 30,  Basic income (loss) per common share 2018 2017 2018 2017  Net income (loss) $ 1,565 $ 1,325 $ (2,064) $ 6,711  Net (income) loss allocated to participating securities (15) (22) 20 (126)  Net income (loss) allocated to common shareholders $ 1,550 $ 1,303 $ (2,044) $ 6,585   Basic weighted-average common shares outstanding 36,526 32,887 36,331 32,665  Basic income (loss) per common share $ 0.04 $ 0.04 $ (0.06) $ 0.20   Three Months Ended Nine Months Ended  September 30, September 30,  Diluted income (loss) per common share 2018 2017 2018 2017  Net income (loss) $ 1,565 $ 1,325 $ (2,064) $ 6,711  Net (income) loss allocated to participating securities (14) (22) 20 (122)  Net income (loss) allocated to common shareholders $ 1,551 $ 1,303 $ (2,044) $ 6,589   Basic weighted-average common shares outstanding 36,526 32,887 36,331 32,665  Effect of dilutive stock options and awards 1,084 1,170 -- 1,186  Diluted weighted-average common shares outstanding 37,610 34,057 36,331 33,851  Diluted income (loss) per common share $ 0.04 $ 0.04 $ (0.06) $ 0.19 We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income (loss) per common share. F or the three months ended September 30, 2018 none of the stock options to purchase shares were antidilutive ; therefore, no shares were excluded from the calculation of diluted weighted-average common shares outstanding. For the nine months ended September 30, 2018 all stock options and awards were excluded from the calculation of diluted weighted-average common shares outstanding as these would be antidilutive due to the net loss. For the three and nine months ended September 30, 2017 stock options to purchase a weighted-average 264,000 shares and 215,000 shares, respectively, were antidilutive and excluded from the calculation of diluted weighted-average common shares outstanding.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2018
Segment Information [Abstract]
Segment Information	14. Segment Information We have two reportable segments organized according to our products and services: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue; BioFoam ® Surgical Matrix; JOTEC products, since the JOTEC Acquisition; On-X products; CardioGenesis cardiac laser therapy; PerClot; and PhotoFix. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. There are no intersegment revenues.  The primary measure of segment performance, as viewed by our management, is segment gross margin, or net external revenues less cost of products and preservation services. We do not segregate assets by segment; therefore, asset information is excluded from the segment disclosures below.  The following table summarizes revenues, cost of products and preservation services, and gross margins for our operating segments (in thousands):    Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Revenues:  Medical devices $ 45,152 $ 27,029 $ 138,063 $ 84,519  Preservation services 19,446 16,970 56,979 52,357  Total revenues 64,598 43,999 195,042 136,876   Cost of products and preservation services:  Medical devices 12,459 6,220 40,166 21,196  Preservation services 9,425 7,917 27,083 23,401  Total cost of products and preservation services 21,884 14,137 67,249 44,597   Gross margin:  Medical devices 32,693 20,809 97,897 63,323  Preservation services 10,021 9,053 29,896 28,956  Total gross margin $ 42,714 $ 29,862 $ 127,793 $ 92,279  The following table summarizes net revenues by product and service (in thousands):           Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Products:  BioGlue and BioFoam $ 15,646 $ 15,730 $ 48,685 $ 48,094  JOTEC 15,004 -- 46,669 --  On-X 11,298 8,326 33,495 27,048  CardioGenesis cardiac laser therapy 1,590 1,489 4,514 5,130  PerClot 882 886 2,822 2,641  PhotoFix 732 598 1,878 1,606  Total products 45,152 27,029 138,063 84,519   Preservation services:  Cardiac tissue 9,502 7,932 26,660 23,911  Vascular tissue 9,944 9,038 30,319 28,446  Total preservation services 19,446 16,970 56,979 52,357   Total revenues $ 64,598 $ 43,999 $ 195,042 $ 136,876  

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Financial Instruments [Abstract]
Summary Of Financial Instruments Measured At Fair Value	   September 30, 2018 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 1,237 $ -- $ -- $ 1,237  Restricted securities:  Money market funds 753 -- -- 753  Total assets $ 1,990 $ -- $ -- $ 1,990     December 31, 2017 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 372 $ -- $ -- $ 372  Restricted securities:  Money market funds 776 -- -- 776  Total assets $ 1,148 $ -- $ -- $ 1,148 

Cash Equivalents And Restrict_2

Cash Equivalents And Restricted Securities (Tables)	9 Months Ended
	Sep. 30, 2018
Cash Equivalents And Restricted Securities [Abstract]
Summary Of Cash Equivalents And Restricted Securities	  Unrealized Estimated  Holding Market  September 30, 2018 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 1,237 $ -- $ 1,237  Restricted securities:  Money market funds 753 -- 753   Unrealized Estimated  Holding Market  December 31, 2017 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 372 $ -- $ 372  Restricted securities:  Money market funds 776 -- 776 

Acquisition Of JOTEC (Tables)

Acquisition Of JOTEC (Tables) - JOTEC [Member]	9 Months Ended
	Sep. 30, 2018
Purchase Price Allocation	  Opening  Balance Sheet  Cash and cash equivalents $ 4,130  Receivables 13,392  Inventories 17,393  Intangible assets 111,711  Property and equipment, net 13,051  Goodwill 112,431  Other assets 4,281  Debt acquired (3,808)  Liabilities assumed (50,424)  Total purchase price $ 222,157 
Pro Forma Information	  Twelve Months Ended  December 31,  2017 2016  Total revenues $ 236,209 $ 224,896  Net loss (736) (1,966)   Pro forma loss per common share - basic $ (0.02) $ (0.06)  Pro forma loss per common share - diluted $ (0.02) $ (0.06) 

Inventories And Deferred Pres_2

Inventories And Deferred Preservation Costs (Tables)	9 Months Ended
	Sep. 30, 2018
Inventories And Deferred Preservation Costs [Abstract]
Schedule Of Inventories	  September 30, December 31,  2018 2017  Raw materials and supplies $ 16,858 $ 16,328  Work-in-process 4,093 5,504  Finished goods 25,198 24,852  Total inventories $ 46,149 $ 46,684 
Schedule Of Deferred Preservation Costs	  September 30, December 31,  2018 2017  Cardiac tissues $ 16,077 $ 16,988  Vascular tissues 17,432 18,683  Total deferred preservation costs $ 33,509 $ 35,671 

Goodwill And Other Intangible_2

Goodwill And Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Carrying Values Of Indefinite Lived Intangible Assets	  September 30, December 31,  2018 2017  Goodwill $ 188,118 $ 188,305  In-process R&D 9,485 13,954  Procurement contracts and agreements 2,013 2,013  Trademarks 841 841 
Schedule Of Goodwill By Reportable Segment	  Medical Devices Segment  Balance as of December 31, 2017 $ 188,305  JOTEC Acquisition measurement period adjustments 3,177  Revaluation of goodwill denominated in foreign currency (3,364)  Balance as of September 30, 2018 $ 188,118 
Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets	  Gross Carrying Accumulated Amortization  September 30, 2018 Value Amortization Period  Acquired technology $ 136,061 $ 14,807 11 – 22 Years  Customer lists and relationships 31,191 4,702 13 – 22 Years  Distribution and manufacturing rights and know-how 4,059 2,035 11 – 15 Years  Patents 3,621 2,918 17 Years  Other 2,096 1,467 3 – 5 Years   Gross Carrying Accumulated Amortization  December 31, 2017 Value Amortization Period  Acquired technology $ 139,045 $ 8,686 11 – 22 Years  Customer lists and relationships 32,419 3,552 13 – 23 Years  Distribution and manufacturing rights and know-how 4,059 1,820 11 – 15 Years  Patents 3,612 2,819 17 Years  Other 1,439 1,075 3 Years 
Summary Of Amortization Expense	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Amortization expense $ 2,707 $ 1,140 $ 8,195 $ 3,423 
Scheduled Amortization Of Intangible Assets For Next Five Years	  Remainder  of 2018 2019 2020 2021 2022 2023 Total  Amortization expense $ 2,597 $ 10,386 $ 10,222 $ 10,202 $ 9,673 $ 9,287 $ 52,367 

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt [Abstract]
Schedule Of Short-Term And Long-Term Balances Of Term Loan	  September 30, December 31,  2018 2017  Term loan balance $ 223,313 $ 225,000  2.45% Sparkasse Zollernalb (KFW Loan 1) 1,401 1,657  1.40% Sparkasse Zollernalb (KFW Loan 2) 1,989 2,312  Total loan balance 226,703 228,969  Less unamortized loan origination costs (8,858) (10,015)  Net borrowings 217,845 218,954  Less short-term loan balance (1,266) (718)  Long-term loan balance $ 216,579 $ 218,236 

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Disaggregation Of Revenue	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  (Unaudited) (Unaudited)  Domestic hospitals $ 34,924 $ 30,720 $ 103,606 $ 95,327  International hospitals 19,001 5,158 56,440 12,291  International distributors 9,083 6,632 30,482 24,128  CardioGenesis cardiac laser therapy 1,590 1,489 4,514 5,130  Total sources of revenue $ 64,598 $ 43,999 $ 195,042 $ 136,876 

Stock Compensation (Tables)

Stock Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Stock Compensation [Abstract]
Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options	  Three Months Ended Nine Months Ended  September 30, 2018 September 30, 2018  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options N/A 0.5 Years 5.0 Years 0.5 Years  Expected stock price volatility N/A 0.32 0.40 0.35  Risk-free interest rate N/A 2.11% 2.64% 1.53%     Three Months Ended Nine Months Ended  September 30, 2017 September 30, 2017  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options N/A 0.5 Years 4.8 Years 0.5 Years  Expected stock price volatility N/A 0.43 0.40 0.35  Risk-free interest rate N/A 1.14% 1.87% 0.62%   
Summary Of Total Stock Compensation Expenses	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  RSA, PSA, RSU, and PSU expense $ 1,281 $ 1,448 $ 3,750 $ 4,326  Stock option and ESPP option expense 412 519 1,301 1,614  Total stock compensation expense $ 1,693 $ 1,967 $ 5,051 $ 5,940 

Income (Loss) Per Common Share

Income (Loss) Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2018
Income (Loss) Per Common Share [Abstract]
Computation Of Basic And Diluted Income Per Common Share	  Three Months Ended Nine Months Ended  September 30, September 30,  Basic income (loss) per common share 2018 2017 2018 2017  Net income (loss) $ 1,565 $ 1,325 $ (2,064) $ 6,711  Net (income) loss allocated to participating securities (15) (22) 20 (126)  Net income (loss) allocated to common shareholders $ 1,550 $ 1,303 $ (2,044) $ 6,585   Basic weighted-average common shares outstanding 36,526 32,887 36,331 32,665  Basic income (loss) per common share $ 0.04 $ 0.04 $ (0.06) $ 0.20   Three Months Ended Nine Months Ended  September 30, September 30,  Diluted income (loss) per common share 2018 2017 2018 2017  Net income (loss) $ 1,565 $ 1,325 $ (2,064) $ 6,711  Net (income) loss allocated to participating securities (14) (22) 20 (122)  Net income (loss) allocated to common shareholders $ 1,551 $ 1,303 $ (2,044) $ 6,589   Basic weighted-average common shares outstanding 36,526 32,887 36,331 32,665  Effect of dilutive stock options and awards 1,084 1,170 -- 1,186  Diluted weighted-average common shares outstanding 37,610 34,057 36,331 33,851  Diluted income (loss) per common share $ 0.04 $ 0.04 $ (0.06) $ 0.19 

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Information [Abstract]
Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Revenues:  Medical devices $ 45,152 $ 27,029 $ 138,063 $ 84,519  Preservation services 19,446 16,970 56,979 52,357  Total revenues 64,598 43,999 195,042 136,876   Cost of products and preservation services:  Medical devices 12,459 6,220 40,166 21,196  Preservation services 9,425 7,917 27,083 23,401  Total cost of products and preservation services 21,884 14,137 67,249 44,597   Gross margin:  Medical devices 32,693 20,809 97,897 63,323  Preservation services 10,021 9,053 29,896 28,956  Total gross margin $ 42,714 $ 29,862 $ 127,793 $ 92,279 
Summary Of Net Revenues By Product And Service	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Products:  BioGlue and BioFoam $ 15,646 $ 15,730 $ 48,685 $ 48,094  JOTEC 15,004 -- 46,669 --  On-X 11,298 8,326 33,495 27,048  CardioGenesis cardiac laser therapy 1,590 1,489 4,514 5,130  PerClot 882 886 2,822 2,641  PhotoFix 732 598 1,878 1,606  Total products 45,152 27,029 138,063 84,519   Preservation services:  Cardiac tissue 9,502 7,932 26,660 23,911  Vascular tissue 9,944 9,038 30,319 28,446  Total preservation services 19,446 16,970 56,979 52,357   Total revenues $ 64,598 $ 43,999 $ 195,042 $ 136,876 

Financial Instruments (Summary

Financial Instruments (Summary Of Financial Instruments Measured At Fair Value) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	$ 1,990	$ 1,148
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	1,237	372
Restricted securities	753	776
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	1,990	1,148
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	1,237	372
Restricted securities	753	776
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 2 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 3 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities

Cash Equivalents And Restrict_3

Cash Equivalents And Restricted Securities (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 753,000		$ 753,000		$ 776,000
Gross realized gains or losses on cash equivalents	0	$ 0	0	$ 0
Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	753,000		753,000		776,000
Maturity Date Within Three Months [Member] | Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	231,000		231,000		537,000
Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 522,000		$ 522,000		$ 239,000
Minimum [Member] | Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			3 months		3 months
Maximum [Member] | Maturity Date Within Three Months [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			3 months		3 months
Maximum [Member] | Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			1 year		1 year

Cash Equivalents And Restrict_4

Cash Equivalents And Restricted Securities (Summary Of Cash Equivalents And Restricted Securities) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	$ 35,311	$ 40,753	$ 55,013	$ 57,341
Restricted Securities, Cost Basis	753	776
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	1,237	372
Restricted Securities, Cost Basis	753	776
Unrealized Holding Gains
Cash Equivalents, Estimated Market Value	1,237	372
Restricted Securities, Estimated Market Value	$ 753	$ 776

Acquisition Of JOTEC (Narrative

Acquisition Of JOTEC (Narrative) (Details) - USD ($) $ in Thousands	Dec. 01, 2017	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Term loan balance		$ 228,969	$ 226,703	$ 226,703	$ 228,969
JOTEC acquisition measurement period adjustments				$ 3,177
JOTEC [Member]
Business Acquisition [Line Items]
Agreement date				Dec. 1, 2017
Acquisition price	$ 225,000
Total consideration	222,157
Cash consideration	169,100
Common shares issued					2,682,754
Common stock value issued in business combination					$ 53,100
Escrow deposit, part of payments to acquire business	$ 22,500
Transaction and integration costs			1,800	$ 6,100
Revenues		4,100
Net loss		(1,500)			$ (736)	$ (1,966)
Pro forma tax rate					38.00%	38.00%
JOTEC [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Common shares issued	2,682,754
Common stock value issued in business combination	$ 53,100
Term Loan [Member]
Business Acquisition [Line Items]
Term loan balance	225,000	$ 225,000	$ 223,313	$ 223,313	$ 225,000
Term Loan [Member] | JOTEC [Member]
Business Acquisition [Line Items]
Term loan balance	225,000
Senior Secured Credit Facility [Member] | JOTEC [Member]
Business Acquisition [Line Items]
Credit facility aggregate commitments	255,000
Revolving Credit Facility [Member] | JOTEC [Member]
Business Acquisition [Line Items]
Credit facility aggregate commitments	$ 30,000

Acquisition Of JOTEC (Purchase

Acquisition Of JOTEC (Purchase Price Allocation) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Dec. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 188,118	$ 188,305
JOTEC [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 4,130
Receivables			13,392
Inventories			17,393
Intangible assets			111,711
Property and equipment			13,051
Goodwill			112,431
Other assets			4,281
Debt acquired			(3,808)
Liabilities assumed			(50,424)
Total purchase consideration			$ 222,157

Acquisition Of JOTEC (Pro Forma

Acquisition Of JOTEC (Pro Forma Information) (Details) - JOTEC [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Total revenues		$ 236,209	$ 224,896
Net loss	$ (1,500)	$ (736)	$ (1,966)
Pro forma loss per common share - basic		$ (0.02)	$ (0.06)
Pro forma loss per common share - diluted		$ (0.02)	$ (0.06)

Inventories And Deferred Pres_3

Inventories And Deferred Preservation Costs (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Inventory [Line Items]
Consignment inventory	$ 10.6	$ 9.3
Domestic [Member]
Inventory [Line Items]
Consignment inventory percentage	58.00%	58.00%
Foreign [Member]
Inventory [Line Items]
Consignment inventory percentage	42.00%	42.00%

Inventories And Deferred Pres_4

Inventories And Deferred Preservation Costs (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventories And Deferred Preservation Costs [Abstract]
Raw materials and supplies	$ 16,858	$ 16,328
Work-in-process	4,093	5,504
Finished goods	25,198	24,852
Total inventories	$ 46,149	$ 46,684

Inventories And Deferred Pres_5

Inventories And Deferred Preservation Costs (Schedule Of Deferred Preservation Costs) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total deferred preservation costs	$ 33,509	$ 35,671
Cardiac Tissues [Member]
Total deferred preservation costs	16,077	16,988
Vascular Tissues [Member]
Total deferred preservation costs	$ 17,432	$ 18,683

Goodwill And Other Intangible_3

Goodwill And Other Intangible Assets (Schedule Of Carrying Values Of Indefinite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 188,118	$ 188,305
In Process R&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	9,485	13,954
Procurement Contracts And Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	2,013	2,013
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	$ 841	$ 841

Goodwill And Other Intangible_4

Goodwill And Other Intangible Assets (Schedule Of Goodwill By Reportable Segment) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Goodwill [Line Items]
Beginning balance	$ 188,305
JOTEC acquisition measurement period adjustments	3,177
Revaluation of goodwill denominated in foreign currency	(3,364)
Ending balance	$ 188,118

Goodwill And Other Intangible_5

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 136,061	$ 139,045
Accumulated amortization	14,807	8,686
Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	31,191	32,419
Accumulated amortization	4,702	3,552
Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,059	4,059
Accumulated amortization	2,035	1,820
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,621	3,612
Accumulated amortization	2,918	2,819
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2,096	1,439
Accumulated amortization	$ 1,467	$ 1,075
Minimum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	13 years	13 years
Minimum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	3 years
Maximum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	22 years
Maximum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	23 years
Maximum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	15 years	15 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	17 years	17 years
Maximum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	5 years	3 years

Goodwill And Other Intangible_6

Goodwill And Other Intangible Assets (Summary Of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Goodwill And Other Intangible Assets [Abstract]
Amortization expense	$ 2,707	$ 1,140	$ 8,195	$ 3,423

Goodwill And Other Intangible_7

Goodwill And Other Intangible Assets (Scheduled Amortization Of Intangible Assets For Next Five Years) (Details) $ in Thousands	Sep. 30, 2018USD ($)
Goodwill And Other Intangible Assets [Abstract]
Remainder of 2018	$ 2,597
2,019	10,386
2,020	10,222
2,021	10,202
2,022	9,673
2,023	9,287
Total	$ 52,367

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Taxes [Abstract]
Effective income tax rate	26.00%		58.00%	14.00%
Increase in income tax benefit	$ 1,400,000	$ 1,100,000		$ 2,700,000
Tax provision			$ 565,000
Valuation allowances against deferred tax assets	2,500,000		2,500,000		$ 2,500,000
Net deferred tax liability	$ 22,700,000		$ 22,700,000		$ 28,800,000

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2018	Jun. 30, 2015	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 01, 2017
Line of Credit Facility [Line Items]
Term loan balance			$ 226,703,000		$ 226,703,000		$ 228,969,000
Credit facility default interest rate			2.00%		2.00%
Credit facility aggregate interest rate			6.39%		6.39%
Credit facility commitment fee percentage					0.50%
Line of credit facility, percentage threshold of principal amount outstanding					25.00%
Interest expense			$ 4,100,000	$ 851,000	$ 11,900,000	$ 2,500,000
Government Sponsored Debt [Member]
Line of Credit Facility [Line Items]
Loan term		9 years
2.45% Sparkasse Zollernalb (KFW Loan 1) [Member]
Line of Credit Facility [Line Items]
Term loan balance			1,401,000		1,401,000		1,657,000
Interest rate on amounts borrowed		2.45%
1.4% Sparkasse Zollernalb (KFW Loan 2) [Member]
Line of Credit Facility [Line Items]
Term loan balance			1,989,000		$ 1,989,000		2,312,000
Interest rate on amounts borrowed		1.40%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility maturity date					Dec. 1, 2022
Credit facility outstanding balance			0		$ 0		0
Credit facility remaining availability			30,000,000		$ 30,000,000
Revolving Credit Facility [Member] | JOTEC [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments								$ 30,000,000
Revolving Credit Facility [Member] | Minimum [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin					3.00%
Revolving Credit Facility [Member] | Minimum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin					4.00%
Revolving Credit Facility [Member] | Maximum [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin					3.25%
Revolving Credit Facility [Member] | Maximum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin					4.25%
Senior Secured Credit Facility [Member] | JOTEC [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments								255,000,000
Term Loan [Member]
Line of Credit Facility [Line Items]
Term loan balance			$ 223,313,000		$ 223,313,000		$ 225,000,000	225,000,000
Credit facility maturity date					Dec. 1, 2024
Term Loan [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin					3.00%
Term Loan [Member] | Base Rate [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Credit facility margin	2.25%
Term Loan [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin					4.00%
Term Loan [Member] | LIBOR [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Credit facility margin	3.25%
Term Loan [Member] | JOTEC [Member]
Line of Credit Facility [Line Items]
Term loan balance								$ 225,000,000

Debt (Schedule Of Short-Term An

Debt (Schedule Of Short-Term And Long-Term Balances Of Term Loan) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Dec. 01, 2017
Debt Instrument [Line Items]
Term loan balance	$ 226,703	$ 228,969
Less unamortized loan origination costs	(8,858)	(10,015)
Net borrowings	217,845	218,954
Less short-term loan balance	(1,266)	(718)
Long-term loan balance	216,579	218,236
2.45% Sparkasse Zollernalb (KFW Loan 1) [Member]
Debt Instrument [Line Items]
Term loan balance	1,401	1,657
1.4% Sparkasse Zollernalb (KFW Loan 2) [Member]
Debt Instrument [Line Items]
Term loan balance	1,989	2,312
Term Loan [Member]
Debt Instrument [Line Items]
Term loan balance	$ 223,313	$ 225,000	$ 225,000

Commitments And Contingencies (

Commitments And Contingencies (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Other Commitments [Line Items]
Unreported loss liability	$ 1,900	$ 1,800
Recoverable insurance amounts	773	692
Net intangible assets	121,254	130,359
Property and equipment, net	32,072	$ 33,579
PerClot [Member]
Other Commitments [Line Items]
Prepaid royalties	1,500
Net intangible assets	2,400
Property and equipment, net	1,400
Maximum [Member]
Other Commitments [Line Items]
Estimated loss	$ 3,100
Starch Technology Purchase [Member]
Other Commitments [Line Items]
Term of distribution agreement	15 years
Expected future contingent payment amounts	$ 1,000
Number of notice days	180 days

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - JOTEC [Member] $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)shares
Equity, Class of Treasury Stock [Line Items]
Common shares issued | shares	2,682,754
Common stock consideration | $	$ 53.1

Revenue Recognition (Disaggrega

Revenue Recognition (Disaggregation Of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total Sources of Revenue	$ 64,598	$ 43,999	$ 195,042	$ 136,876
Domestic Hospitals [Member]
Disaggregation of Revenue [Line Items]
Total Sources of Revenue	34,924	30,720	103,606	95,327
International Hospitals [Member]
Disaggregation of Revenue [Line Items]
Total Sources of Revenue	19,001	5,158	56,440	12,291
International Distributor [Member]
Disaggregation of Revenue [Line Items]
Total Sources of Revenue	9,083	6,632	30,482	24,128
CardioGenesis Cardiac Laser Therapy [Member]
Disaggregation of Revenue [Line Items]
Total Sources of Revenue	$ 1,590	$ 1,489	$ 4,514	$ 5,130

Stock Compensation (Narrative)

Stock Compensation (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capitalized stock compensation expense	$ 125	$ 111	$ 363	$ 288
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees			85.00%
Employees purchased common stock, shares	46,000	47,000	82,000	93,000
RSAs, RSUs, And PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans			317,000	384,000
Aggregate grant date market value			$ 7,100	$ 6,300
Unrecognized compensation costs	$ 7,900		7,900
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$ 2,200		$ 2,200
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 8 months 12 days
Restricted Stock Awards (RSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 2 months 12 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 10 months 24 days
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans				0
Percentage of target number of shares of common stock granted as Performance Stock Units					100.00%
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year
Minimum [Member] | Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			60.00%		60.00%
Maximum [Member] | Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			150.00%		150.00%
Officers [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants of stock options			219,000	260,000

Stock Compensation (Schedule Of

Stock Compensation (Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options			5 years	4 years 9 months 18 days
Expected stock price volatility			0.40%	0.40%
Risk-free interest rate			2.64%	1.87%
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	6 months	6 months	6 months	6 months
Expected stock price volatility	0.32%	0.43%	0.35%	0.35%
Risk-free interest rate	2.11%	1.14%	1.53%	0.62%

Stock Compensation (Summary Of

Stock Compensation (Summary Of Total Stock Compensation Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,693	$ 1,967	$ 5,051	$ 5,940
RSA, PSA, RSU, And PSU Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1,281	1,448	3,750	4,326
Stock Option And ESPP Option Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 412	$ 519	$ 1,301	$ 1,614

Income (Loss) Per Common Shar_2

Income (Loss) Per Common Share (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2017
Income (Loss) Per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	0	264,000	215,000

Income (Loss) Per Common Shar_3

Income (Loss) Per Common Share (Computation Of Basic And Diluted Income Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Basic income (loss) per common share
Net income (loss)	$ 1,565	$ 1,325	$ (2,064)	$ 6,711
Net (income) loss allocated to participating securities	(15)	(22)	20	(126)
Net income (loss) allocated to common shareholders	$ 1,550	$ 1,303	$ (2,044)	$ 6,585
Basic weighted-average common shares outstanding	36,526	32,887	36,331	32,665
Basic income (loss) per common share	$ 0.04	$ 0.04	$ (0.06)	$ 0.20
Diluted income (loss) per common share
Net income (loss)	$ 1,565	$ 1,325	$ (2,064)	$ 6,711
Net (income) loss allocated to participating securities	(14)	(22)	20	(122)
Net income (loss) allocated to common shareholders	$ 1,551	$ 1,303	$ (2,044)	$ 6,589
Basic weighted-average common shares outstanding	36,526	32,887	36,331	32,665
Effect of dilutive stock options and awards	1,084	1,170		1,186
Diluted weighted-average common shares outstanding	37,610	34,057	36,331	33,851
Diluted income (loss) per common share	$ 0.04	$ 0.04	$ (0.06)	$ 0.19

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segment	Sep. 30, 2017USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Revenues	$ 64,598	$ 43,999	$ 195,042	$ 136,876
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues			$ 0

Segment Information (Revenues,

Segment Information (Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Total revenues	$ 64,598	$ 43,999	$ 195,042	$ 136,876
Total cost of products and preservation services	21,884	14,137	67,249	44,597
Total gross margin	42,714	29,862	127,793	92,279
Operating Segments [Member] | Medical Devices [Member]
Segment Reporting Information [Line Items]
Total revenues	45,152	27,029	138,063	84,519
Total cost of products and preservation services	12,459	6,220	40,166	21,196
Total gross margin	32,693	20,809	97,897	63,323
Operating Segments [Member] | Preservation Services [Member]
Segment Reporting Information [Line Items]
Total revenues	19,446	16,970	56,979	52,357
Total cost of products and preservation services	9,425	7,917	27,083	23,401
Total gross margin	$ 10,021	$ 9,053	$ 29,896	$ 28,956

Segment Information (Summary Of

Segment Information (Summary Of Net Revenues By Product And Service) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Product Information [Line Items]
Total revenues	$ 64,598	$ 43,999	$ 195,042	$ 136,876
BioGlue And BioFoam [Member]
Product Information [Line Items]
Total revenues	15,646	15,730	48,685	48,094
JOTEC [Member]
Product Information [Line Items]
Total revenues	15,004		46,669
On-X [Member]
Product Information [Line Items]
Total revenues	11,298	8,326	33,495	27,048
CardioGenesis Cardiac Laser Therapy [Member]
Product Information [Line Items]
Total revenues	1,590	1,489	4,514	5,130
PerClot [Member]
Product Information [Line Items]
Total revenues	882	886	2,822	2,641
PhotoFix [Member]
Product Information [Line Items]
Total revenues	732	598	1,878	1,606
Cardiac Tissues [Member]
Product Information [Line Items]
Total revenues	9,502	7,932	26,660	23,911
Vascular Tissues [Member]
Product Information [Line Items]
Total revenues	9,944	9,038	30,319	28,446
Preservation Services [Member]
Product Information [Line Items]
Total revenues	19,446	16,970	56,979	52,357
Operating Segments [Member] | Total Products [Member]
Product Information [Line Items]
Total revenues	45,152	27,029	138,063	84,519
Operating Segments [Member] | Total Preservation Services [Member]
Product Information [Line Items]
Total revenues	$ 19,446	$ 16,970	$ 56,979	$ 52,357